Paricalcitol Tied to Lower Mortality Than Calcitriol in CKD

Kidney disease scrambles the body's vitamin D machinery well before a patient ever reaches dialysis, and the fallout reaches beyond bone density into blood pressure control, immune signaling, and, new evidence suggests, survival itself. A review comparing the major vitamin D therapies used to manage chronic kidney disease (CKD) found that paricalcitol stood out among active vitamin D agents for controlling secondary hyperparathyroidism and, in several large analyses, improving survival relative to calcitriol and other options.¹

A Widespread but Under-Addressed Deficiency

Vitamin D deficiency is common even in the general population: roughly 28.9% of US adults are deficient and another 41.4% are insufficient, per National Health and Nutrition Examination Survey data cited in the review. The kidneys are responsible for converting vitamin D into its hormonally active form, so deficiency becomes more prevalent, and harder to correct, as kidney function declines; individual studies have put the prevalence among patients with CKD anywhere from 30% to 86%, worsening at each successive disease stage. The NIH Office of Dietary Supplements likewise notes that vitamin D insufficiency and deficiency are common among individuals with CKD or receiving dialysis, and that kidney disease experts recommend correcting it to help prevent secondary hyperparathyroidism.²

Left unchecked, that cascade of declining vitamin D activation, shifting calcium-phosphate balance, and rising parathyroid hormone (PTH) can drive bone loss, vascular calcification, and anemia, and in severe cases, has been linked to tendon rupture and calciphylaxis.¹ Reversing the underlying gland changes has proven difficult, but several small studies have shown that sustained calcitriol therapy can shrink parathyroid gland volume and improve bone histology over time.

Comparing Nutritional, Semi-Active, and Active Agents

The review, from researchers at the Warren Alpert Medical School of Brown University, synthesized decades of physiological and clinical trial evidence spanning three drug classes: nutritional vitamin D (cholecalciferol and ergocalciferol), semi-active agents (calcifediol and doxercalciferol), and active agents (calcitriol and paricalcitol). The studies drawn on ranged from small single-center pilots to multicenter, placebo-controlled trials enrolling several hundred patients across CKD stages 2 through hemodialysis dependence, along with meta-analyses pooling thousands of participants.

Evidence for nutritional vitamin D was mixed: supplementation lowered PTH in some individual cohorts but showed no significant pooled effect across multiple randomized trials in either pre-dialysis or dialysis populations. Semi-active agents performed more consistently on that front. In a placebo-controlled trial of 429 patients with CKD stage 3 to 4, calcifediol produced a significant PTH reduction regardless of CKD stage (P < .001), and doxercalciferol cut PTH by 46% after 24 weeks in a separate cohort. Yet a 24-month trial of calcifediol in 284 patients on hemodialysis found no reduction in all-cause or cardiovascular mortality, underscoring a recurring theme: agents that reliably move lab values have not consistently moved survival.

Paricalcitol's Survival Signal

Among active agents, paricalcitol repeatedly outperformed calcitriol. In the PENNY trial (NCT01680198), 88 patients with CKD stage 3 to 4 randomized to paricalcitol saw PTH fall by a mean of 75.1 pg/mL more than placebo (95% CI, –90.4 to –59.8; P < .001). A meta-analysis of four trials in patients on ACE inhibitors or angiotensin receptor blockers found paricalcitol nearly doubled the likelihood of a meaningful proteinuria reduction (risk ratio [RR], 1.68; 95% CI, 1.25-2.25; P < .001), and a pooled analysis combining paricalcitol and calcitriol trials linked active vitamin D therapy to fewer cardiovascular events (RR, 0.27; 95% CI, 0.13-0.59).

The starkest signal came from a retrospective review of 69,492 patients on hemodialysis, where those treated with paricalcitol had fewer deaths than those treated with calcitriol (3417 vs 6805; rate ratio, 0.80; 95% CI, 0.77-0.84; P < .001), a survival advantage a later meta-analysis of observational studies corroborated (pooled HR, 0.86; 95% CI, 0.80-0.91; P < .00001). Paricalcitol also appeared to carry a lower risk of hypercalcemia and hyperphosphatemia than calcitriol. Still, the authors cautioned that most of this survival evidence is observational rather than randomized, and a separate meta-analysis of more than 11,000 participants failed to confirm an overall mortality benefit from active vitamin D supplementation.

“Supplementation of vitamin D or its analogues can be beneficial in the CKD population regardless of dialysis dependency,” the researchers wrote. “However, conclusive evidence demonstrating its impact on key clinical outcomes, particularly survival, remains limited.” For clinicians and payers, the takeaway is that vitamin D therapy in CKD is not a single decision but a series of them, requiring agent selection tailored to CKD stage and PTH severity, routine monitoring of calcium and phosphorus, and realistic expectations until larger prospective trials clarify which patients stand to gain the most.

References

1. Shringi S, Lu J, Tang J. Management of vitamin D in chronic kidney disease. R I Med J. 2026;109(6):62-68.
2. Office of Dietary Supplements, National Institutes of Health. Vitamin D: fact sheet for health professionals. Updated May 14, 2026. Accessed July 30, 2026. https://ods.od.nih.gov/factsheets/VitaminD-HealthProfessional/